Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection | Zendy

Christopher W. Mullins | Zendy; Geoffrey Eisen | Zendy; STEPHEN J. POPPER | Zendy; A. Sarr | Zendy; Jean-Louis Sankalé | Zendy; J. J. Berger | Zendy; Sharon B. Wright | Zendy; H. R. Chang | Zendy; G Coste | Zendy; Timothy P. Cooley | Zendy; Peter A. Rice | Zendy; Paul R. Skolnik | Zendy; M Sullivan | Zendy; Phyllis J. Kanki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

Author(s) -

Christopher W. Mullins,

Geoffrey Eisen,

STEPHEN J. POPPER,

A. Sarr,

Jean-Louis Sankalé,

J. J. Berger,

Sharon B. Wright,

H. R. Chang,

G Coste,

Timothy P. Cooley,

Peter A. Rice,

Paul R. Skolnik,

M Sullivan,

Phyllis J. Kanki

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/421390

Subject(s) - medicine , viral load , sida , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , lentivirus , retrovirus , viral disease , virology , virus , clinical trial , combination therapy

Human immunodeficiency virus type 2 (HIV-2), the second human retrovirus known to cause AIDS, is endemic to West Africa but is infrequently found outside this region. We present a case series of 10 HIV-2--infected individuals treated in the United States. Physicians applied the principles of highly active antiretroviral therapy (HAART), normally used in treating HIV type 1, with modifications considered appropriate for treating HIV-2. CD4+ cell count, HIV-2 virus load, and clinical status were found to correlate well, providing evidence that HIV-2 virus load is useful in managing treatment of patients with HIV-2 who are receiving therapy. However, HAART regimens with predicted efficacy for treatment of HIV type 1 infection are not as efficacious for treatment of HIV-2. Controlled clinical trials of HIV-2-infected patients receiving various HAART regimens are needed to provide therapeutic guidance to the medical community.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research